Updated
Updated · TechCrunch · Jul 30
Simile Raises $200 Million at $2 Billion Valuation for Synthetic-User Simulation
Updated
Updated · TechCrunch · Jul 30

Simile Raises $200 Million at $2 Billion Valuation for Synthetic-User Simulation

3 articles · Updated · TechCrunch · Jul 30

Summary

  • $200 million in Series B funding values Simile at $2 billion, just five months after the startup emerged from stealth with a $100 million Series A.
  • Greenoaks led the round, with Index Ventures and other existing backers joining in; CVS Health Ventures also participated, and CVS is already one of Simile’s marquee customers.
  • Simile sells simulated users for marketing and product research, building on founder Joon Sung Park’s Stanford work on “Smallville,” where AI agents modeled human-like lives and interactions.
  • The raise underscores strong VC appetite for synthetic-user research tools, a niche that has also lifted rivals such as Aaru, which reached a $1 billion valuation in its December Series A.

Insights

Can AI “twins” really reveal why patients skip prescriptions, or are cost, trust, and digital confusion still the bigger barriers?
CVS is testing simulated patients to boost medication adherence—but what happens if the AI misunderstands the people most at risk?